MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.

TitleMicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.
Publication TypeJournal Article
Year of Publication2014
AuthorsZimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P
JournalTrends Neurosci
Volume37
Issue11
Pagination629-41
Date Published2014 Nov
ISSN1878-108X
KeywordsAlzheimer Disease, Amyloid beta-Peptides, Animals, Brain, Disease Models, Animal, Humans, Neuroimaging, Positron-Emission Tomography
Abstract

Over the past decades, developments in neuroimaging have significantly contributed to the understanding of Alzheimer's disease (AD) pathophysiology. Specifically, positron emission tomography (PET) imaging agents targeting amyloid deposition have provided unprecedented opportunities for refining in vivo diagnosis, monitoring disease propagation, and advancing AD clinical trials. Furthermore, the use of a miniaturized version of PET (microPET) in transgenic (Tg) animals has been a successful strategy for accelerating the development of novel radiopharmaceuticals. However, advanced applications of microPET focusing on the longitudinal propagation of AD pathophysiology or therapeutic strategies remain in their infancy. This review highlights what we have learned from microPET imaging in Tg models displaying amyloid and tau pathology, and anticipates cutting-edge applications with high translational value to clinical research.

DOI10.1016/j.tins.2014.07.002
Alternate JournalTrends Neurosci.
PubMed ID25151336
Grant ListMOP 10-27-52 / / Canadian Institutes of Health Research / Canada
MOP-11-51-31 / / Canadian Institutes of Health Research / Canada